XML 33 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)
 9 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Other Nonoperating Income (Expense)
The following table summarizes the components of other (expense) income, net.
 Three Months Ended March 31, Nine Months Ended March 31,
2025202420252024
(Losses) gains on derivatives not designated as hedging instruments (1)$(14,640)$9,071 $(1,577)$3,715 
Currency-related gains (losses), net (2)5,131 (12,434)11,691 (2,071)
Other gains (losses)68 (288)631 733 
Total other (expense) income, net$(9,441)$(3,651)$10,745 $2,377 
_____________________
(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized gains of $4,434 and $5,183 for the three and nine months ended March 31, 2025, respectively, and losses of $349 and $838 for the three and nine months ended March 31, 2024, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
(2) Currency-related gains (losses), net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three and nine months ended March 31, 2024, we recognized gains of $1,748 and $1,454, respectively, on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the three and nine months ended March 31, 2025. Refer to Note 4 for additional details regarding our cash flow hedges.
Schedule of Weighted Average Number of Shares
The following table sets forth the reconciliation of the weighted-average number of ordinary shares.
 Three Months Ended March 31, Nine Months Ended March 31,
 2025202420252024
Weighted average shares outstanding, basic
24,834,409 26,216,216 24,990,419 26,432,423 
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2)— — 851,362 711,196 
Shares used in computing diluted net (loss) income per share attributable to Cimpress plc24,834,409 26,216,216 25,841,781 27,143,619 
Weighted average anti-dilutive shares excluded from diluted net (loss) income per share attributable to Cimpress plc (1)(2)
2,083,040 955,594 312,874 127,229 
__________________
(1) In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive.
(2) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three months ended March 31, 2025, the average share price was below the strike price for the quarter; therefore, the total outstanding warrants were considered anti-dilutive. The weighted average anti-dilutive effect of the warrants for the three months ended March 31, 2025 and 2024 was 1,055,377 and 309,000 (anti-dilutive due to our net loss position), respectively, and the weighted average dilutive effect of the warrants for the nine months ended March 31, 2025 and 2024 was 196,438 and 184,608, respectively.